Court invalidates patent for AstraZeneca asthma drug
Reuters reported Sunday that a US District Court in New Jersey has ruled that AstraZeneca's patent for asthma treatment Pulmicort Respules is invalid. The drugmaker is appealing the decision. . In the meantime, based on the court's ruling, Actavis announced that it would launch a generic version of the drug, which reportedly garnered $1.1 billion in branded and generic sales from June 2013 to June 2014. Teva, under agreement with AstraZeneca, already manufactures and markets another copycat of the brand.